The pharmacological management of constipation in patients with Parkinson’s disease: a much-needed relief

References

• Su A, Gandhy R, Barlow C, et al. A practical review of gastrointestinal manifestations in Parkinson’s disease. Parkinsonism Relat Disord. 2017;39:17–26.
   PubMed Web of Science ®Google Scholar
• Akbar U, D’Abreu A, Friedman JH. Nonmotor symptoms in Parkinson’s disease. Semin Neurol. 2017;37:158–166.
   PubMed Web of Science ®Google Scholar
• Barboza JL, Okun MS, Moshiree B. The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson’s disease. Expert Opin Pharmacother. 2015;16:2449–2464.
   PubMed Web of Science ®Google Scholar
• Rossi M, Merello M, Perez-Lloret S. Management of constipation in Parkinson’s disease. Expert Opin Pharmacother. 2015;16:547–557.
   PubMed Web of Science ®Google Scholar
• Lauretani F, Saginario A, Ceda GP, et al. Treatment of the motor and non-motor symptoms in Parkinson’s disease according to cluster symptoms presentation. Curr Drug Targets. 2014;15:943–947.
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Biswas A, Das SK. Gut dysfunction in Parkinson’s disease. World J Gastroenterol. 2016;22:5742–5752.
   PubMed Web of Science ®Google Scholar
• Mozaffari S, Didari T, Nikfar S, et al. Phase II drugs under clinical investigation for the treatment of chronic constipation. Expert Opin Investig Drugs. 2014;23:1485–1497.
   PubMed Web of Science ®Google Scholar
• Sławek J, Madaliński M. Botulinum toxin therapy for nonmotor aspects of Parkinson’s disease. Int Rev Neurobiol. 2017;134:1111–1142.
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A randomized trial of relamorelin for constipation in Parkinson’s disease (MOVE-PD): trial results and lessons learned. Parkinsonism Relat Disord. 2017;37:101–105.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Torti M. Constipation in Parkinson’s disease. Int Rev Neurobiol. 2017;134:811–826.
   PubMed Web of Science ®Google Scholar
• Knudsen K, Fedorova TD, Bekker AC, et al. Objective colonic dysfunction is far more prevalent than subjective constipation in Parkinson’s disease: a colon transit and volume study. J Parkinsons Dis. 2017;7:359–367.
   PubMedGoogle Scholar
• Knudsen K, Haase AM, Fedorova TD, et al. Gastrointestinal transit time in Parkinson’s disease using a magnetic tracking system. J Parkinsons Dis. 2017;7:471–479.
   PubMedGoogle Scholar
• Pellegrini C, Antonioli L, Colucci R, et al. Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatalneurodegeneration. Neuropharmacology. 2017;123:22–33.
   PubMed Web of Science ®Google Scholar
• Tateno F, Sakakibara R, Yokoi Y, et al. Levodopa ameliorated anorectal constipation in de novo Parkinson’s disease: the QL-GAT study. Parkinsonism Relat Disord. 2011;17:615–662.
   Web of Science ®Google Scholar
• Longo WE, Vernava AM 3rd. Prokinetic agents for lower gastrointestinal motility disorders. Dis Colon Rectum. 1993;36:696–708.
   PubMed Web of Science ®Google Scholar
• Zhang H, Gu Z, An J, et al. Non-motor symptoms in treated and untreated Chinese patients with early Parkinson’s disease. Tohoku J Exp Med. 2014;232:129–136.
   PubMed Web of Science ®Google Scholar
• Pagano G, Tan EE, Haider JM, et al. Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21:120–125.
   PubMed Web of Science ®Google Scholar
• Anselmi L, Toti L, Bove C, et al. A nigro-vagal pathway controls gastric motility and is affected in a rat model of parkinsonism. Gastroenterology. 2017;153:1581–1593.
   PubMed Web of Science ®Google Scholar
• Colucci M, Cervio M, Faniglione M, et al. Intestinal dysmotility and enteric neurochemical changes in a Parkinson’s disease rat model. Auton Neurosci. 2012;169:77–86.
   PubMed Web of Science ®Google Scholar
• Anderson G, Noorian AR, Taylor G, et al. Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson’s disease. Exp Neurol. 2007;207:4–1221.
   PubMed Web of Science ®Google Scholar
• Fornai M, Pellegrini C, Antonioli L, et al. Enteric dysfunctions in experimental Parkinson’s disease: alterations of excitatory cholinergic neurotransmission regulating colonic motility in rats. J Pharmacol Exp Ther. 2016;356:434–444.
   PubMed Web of Science ®Google Scholar
• Hinkle JT, Perepezko K, Mills KA, et al. Dopamine transporter availability reflects gastrointestinal dysautonomia in early Parkinson disease. Parkinsonism Relat Disord. 2018;55:8–14.
   PubMed Web of Science ®Google Scholar
• Gjerloff T, Fedorova T, Knudsen K, et al. Imaging acetylcholinesterase density in peripheral organs in Parkinson’s disease with 11C-donepezil PET. Brain. 2015;138:653–663.
   PubMed Web of Science ®Google Scholar
• Levandis G, Balestra B, Siani F, et al. Response of colonic motility to dopaminergic stimulation is subverted in rats with nigrostriatal lesion: relevance to gastrointestinal dysfunctions in Parkinson’s disease. Neurogastroenterol Motil. 2015;27:1783–1795.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li Y, Liu C, et al. Alteration of enteric monoamines with monoamine receptors and colonic dysmotility in 6-hydroxydopamine-induced Parkinson’s disease rats. Transl Res. 2015;166:152–162.
   PubMed Web of Science ®Google Scholar
• Annerino DM, Arshad S, Taylor GM, et al. disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol. 2012;124:665–680.
   PubMed Web of Science ®Google Scholar
• Scharf AB, Deuschl G, Schneider SA, et al. Distinct pattern of enteric phosphoalpha Parkinson’s -synuclein aggregates and gene expression profiles in patients with Parkinson’s disease. Acta Neuropathol Commun. 2017;5:1.
   PubMed Web of Science ®Google Scholar
• Edwards LL, Quigley EM, Harned RK, et al. Defecatory function in Parkinson’s disease: response to apomorphine. Ann Neurol. 1993;33:490–493.
   PubMed Web of Science ®Google Scholar
• Zhu HC, Zhao J, Luo CY, et al. Gastrointestinal dysfunction in a Parkinson’s disease rat model and the changes of dopaminergic, nitric oxidergic, and cholinergic neurotransmitters in myenteric plexus. J Mol Neurosci. 2012;47:15–25.
   PubMed Web of Science ®Google Scholar
• Blandini F, Balestra B, Levandis G, et al. Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson’s disease. Neurosci Lett. 2009;467:203–207.
   PubMed Web of Science ®Google Scholar
• Klingelhoefer L, Reichmann H. The gut and nonmotor symptoms in Parkinson’s disease. Int Rev Neurobiol. 2017;134:787–809.
   PubMed Web of Science ®Google Scholar
• Nair AT, Ramachandran V, Joghee NM, et al. Gut microbiota dysfunction as reliable non-invasive early diagnostic biomarkers in the pathophysiology of Parkinson’s disease: a critical review. J Neurogastroenterol Motil. 2018;24:30–42.
   PubMed Web of Science ®Google Scholar
• Campos-Acuña J, Elgueta D, Pacheco R. T-cell-driven inflammation as a mediator of the gut-brain axis involved in Parkinson’s disease. Front Immunol. 2019;10:239 30.
   Web of Science ®Google Scholar
• Unger MM, Spiegel J, Dillmann KU, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat Disord. 2016;32:66–72.
   PubMed Web of Science ®Google Scholar
• Lai F, Jiang R, Xie W, et al. Intestinal pathology and gut microbiota alterations in a methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson’s disease. Neurochem Res. 2018;43:1986–1999.
   PubMed Web of Science ®Google Scholar
• Pellegrini C, Colucci R, Antonioli L, et al. Intestinal dysfunction in Parkinson’s disease: lessons learned from translational studies and experimental models. Neurogastroenterol Motil. 2016;28:1781–1791.
   PubMed Web of Science ®Google Scholar
• Giancola F, Torresan F, Repossi R, et al. Downregulation of neuronal vasoactive intestinal polypeptide in Parkinson’s disease and chronic constipation. Neurogastroenterol Motil. 2017;29(5):12995.
   Web of Science ®Google Scholar
• Korkmaz OT, Tunçel N. Advantages of vasoactive intestinal peptide for the future treatment of Parkinson’s disease. Curr Pharm Des. 2018;24:4693–4701.
   PubMed Web of Science ®Google Scholar
• McClurg D, Hagen S, Jamieson K, et al. Abdominal massage for the alleviation of symptoms of constipation in people with Parkinson’s: a randomised controlled pilot study. Age Ageing. 2016;45:299–303.
   PubMed Web of Science ®Google Scholar
• Wagle Shukla A, Malaty IA. Botulinum toxin therapy for Parkinson’s disease. Semin Neurol. 2017;37:193–204.
   PubMed Web of Science ®Google Scholar
• Updated AGS Beers Criteria® for Potentially Inappropriate Medic. AGS. Long Beach, CA: American Geriatrics Society (AGS); 2019. Available FROM https://geriatricscareonline.org/ProductAbstract/american-geriatrics-society-updated-beers-criteria-for-potentially-inappropriate-medication-use-in-older-adults/CL001
   Google Scholar
• Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord. 2018;33:372–390.
   PubMed Web of Science ®Google Scholar
• Salari M, Fayyazi E, Mirmosayyeb O. Gastrointestinal dysfunction in idiopathic Parkinsonism: A narrative review. J Res Med Sci. 2016;21:126.
   PubMed Web of Science ®Google Scholar
• Coggrave M, Norton C, Cody JD. Management of faecal incontinence and constipation in adults with central neurological diseases. Cochrane Database Syst Rev. 2014;1:CD002115.
   Google Scholar
• Ashraf W, Pfeiffer RF, Park F, et al. Constipation in Parkinson’s disease: objective assessment and response to psyllium. Mov Disord. 1997;12:946–951.
   PubMed Web of Science ®Google Scholar
• Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study. Mov Disord. 2007;22:1239–1244.
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. Management of autonomic dysfunction in parkinson’s disease. Semin Neurol. 2017;37:176–185.
   PubMed Web of Science ®Google Scholar
• Siegel JD, Di Palma JA. Medical treatment of constipation. Clin Colon Rectal Surg. 2005;18:76–80.
   PubMedGoogle Scholar
• Freitas ME, Alqaraawi A, Lang AE, et al. Linaclotide and prucalopride for management of constipation in patients with parkinsonism. Mov Disord Clin Pract. 2018;5:218–220.
   PubMed Web of Science ®Google Scholar
• Sharma A, Kurek J, Morgan JC, et al. Constipation in Parkinson’s disease: a nuisance or nuanced answer to the pathophysiological puzzle? Curr Gastroenterol Rep. 2018;20:1.
   PubMedGoogle Scholar
• Ondo WG, Kenney C, Sullivan K, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology. 2012;78:1650–1654.
   PubMed Web of Science ®Google Scholar
• Liu Z, Sakakibara R, Odaka T, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord. 2005;20:680–686.
   PubMed Web of Science ®Google Scholar
• Daniali M, Nikfar S, Abdollahi M. An overview of the efficacy and safety of prucalopride for the treatment of chronic idiopathic constipation. Expert Opin Pharmacother. 2019;20(17):2073–2080.
   PubMed Web of Science ®Google Scholar
• Karasawa H, Pietra C, Giuliano C, et al. New ghrelin agonist, HM01 alleviates constipation and L-dopa-delayed gastric emptying in 6-hydroxydopamine rat model of Parkinson’s disease. Neurogastroenterol Motil. 2014;26:1771–1782.
   PubMed Web of Science ®Google Scholar
• Barichella M, Pacchetti C, Bolliri C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: an RCT. Neurology. 2016;87:1274–1280.
   PubMed Web of Science ®Google Scholar
• Georgescu D, Ancusa OE, Georgescu LA, et al. Nonmotor gastrointestinal disorders in older patients with Parkinson’s disease: is there hope? Clin Interv Aging. 2016;11:1601–1608.
   PubMed Web of Science ®Google Scholar
• Sotoudegan F, Daniali M, Hassani S, et al. Reappraisal of probiotics’ safety in human. Food Chem Toxicol. 2019 Jul;129:22–29.
   PubMed Web of Science ®Google Scholar
• Killinger BA, Madaj Z, Sikora JW, et al. The vermiform appendix impacts the risk of developing Parkinson’s disease. Sci Transl Med. 2018;10:eaar5280.
   PubMed Web of Science ®Google Scholar